MIR490: A Potential Drug Target and Biomarker for Inflammatory diseases
MIR490: A Potential Drug Target and Biomarker for Inflammatory diseases
Introduction
Inflammation is a fundamental biological response to tissue damage, infection or injury, which involves various signaling pathways that promote the recruitment of immune cells, production of pro-inflammatory cytokines, and tissue damage. Chronic inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and heart failure, have a significant impact on human health and quality of life. The search for new treatments and biomarkers for these diseases has led to the exploration of various targets, including MIR490.
MIR490: A Novel Nucleotide Repeat
MIR490 is a non-coding RNA molecule that has been identified in various tissues and cell types. It is characterized by a repeated sequence of the nucleotides ATCGCTCGAAGG. The repetitive sequence is approximately 22 nts long and is located upstream of the gene encoding the protein heat shock protein (Hsp70) gene. MIR490 has been shown to play a role in various cellular processes, including DNA replication, gene expression, and stress response.
Inflammation and MIR490
The immune system is a critical component of the inflammatory response to tissue damage and infection. MIR490 has been shown to be involved in the regulation of inflammation. Several studies have demonstrated that MIR490 can induce the production of pro-inflammatory cytokines, such as TNF- 伪, IL-1尾, and IL-6, in various cell types, including immune cells and epithelial cells.
In addition, MIR490 has been shown to enhance the expression of genes involved in the production of pro-inflammatory cytokines. For example, MIR490 has been shown to increase the expression of genes involved in the production of IL-6, TNF-伪, and chemokines, such as PD-L1, IL-10, and G-CSF.
Drug Targeting MIR490
The potential drug targeting of MIR490 is derived from its involvement in the regulation of inflammation and its ability to induce pro-inflammatory cytokines. Drugs that can modulate the activity of MIR490, such as inhibitors of nuclear factor kappa B (NFKB), which is a central regulator of inflammation, has been shown to be effective in treating inflammatory diseases.
One such drug is a small molecule inhibitor, called Compound 1 (C1), which is a potent inhibitor of NFKB signaling. Compound 1 has been shown to decrease the production of pro-inflammatory cytokines in various cell types, including immune cells, and to improve the production of anti-inflammatory cytokines.
Another potential drug targeting MIR490 is a peptide-conjugated nanoparticle, called PcMIR490-NPs. PcMIR490-NPs are designed to selectively target MIR490 in various cell types and to inhibit its pro-inflammatory effects. Preclinical studies have shown that PcMIR490-NPs are effective in protecting against the neurotoxicity of amyloid peptides, which are often used in the treatment of Alzheimer's disease.
Biomarker Potential
The MIR490 gene has also been shown to be involved in the regulation of gene expression and has been used as a potential biomarker for various diseases, including cancer and neurodegenerative diseases. Several studies have demonstrated that MIR490 expression is increased in various types of cancer, including breast, ovarian, and colorectal cancer.
In addition, MIR490 has
Protein Name: MicroRNA 490
The "MIR490 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR490 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G
